Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeGlobeNewsWire • 04/03/24
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoGlobeNewsWire • 03/25/24
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/29/24
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024GlobeNewsWire • 02/15/24
Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/10/24
Amarin stock soars on preliminary 4Q revenue guidance, share buyback planProactive Investors • 01/10/24
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024GlobeNewsWire • 01/10/24
Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its OwnershipBusiness Wire • 12/04/23
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineGlobeNewsWire • 11/12/23
Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/01/23
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance OfficerGlobeNewsWire • 10/31/23
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023GlobeNewsWire • 10/26/23